Charles River Laboratories International, Inc.
CRL
$163.71
-$0.40-0.24%
NYSE
| 06/28/2025 | 03/29/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 4.87% | -1.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.87% | -1.83% | |||
| Cost of Revenue | 0.70% | -6.49% | |||
| Gross Profit | 12.77% | 8.39% | |||
| SG&A Expenses | 5.39% | -9.32% | |||
| Depreciation & Amortization | -13.71% | -27.80% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.17% | -8.03% | |||
| Operating Income | 28.37% | 71.54% | |||
| Income Before Tax | 98.50% | 116.60% | |||
| Income Tax Expenses | 85.40% | 431.80% | |||
| Earnings from Continuing Operations | 103.62% | 112.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 10.27% | 45.32% | |||
| Net Income | 105.45% | 111.87% | |||
| EBIT | 28.37% | 71.54% | |||
| EBITDA | 49.42% | 28.13% | |||
| EPS Basic | 111.82% | 111.92% | |||
| Normalized Basic EPS | 55.46% | 185.52% | |||
| EPS Diluted | 112.00% | 111.85% | |||
| Normalized Diluted EPS | 55.47% | 184.54% | |||
| Average Basic Shares Outstanding | -3.02% | -0.90% | |||
| Average Diluted Shares Outstanding | -3.02% | -0.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||